Moore Capital Management’s Starling Oncology Warrant STLNW Stock Holding History

Moore Capital Management’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-62,500	Closed	-$79K	–	862
2021 Q3	$79K	Hold	62,500	–	–	﹤0.01%	720
2021 Q2	$108K	Hold	62,500	–	–	﹤0.01%	737
2021 Q1	$75K	Hold	62,500	–	–	﹤0.01%	646
2020 Q4	$122K	Hold	62,500	–	–	﹤0.01%	508
2020 Q3	$102K	Hold	62,500	–	–	﹤0.01%	363
2020 Q2	$91K	Buy	+62,500	New	+$89.7K	﹤0.01%	247

Other funds holding STLNW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $278M AUM 50.01% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Moore Capital Management's STLNW Position: Q4 2021 in Review

Moore Capital Management sold out of Starling Oncology Warrant (STLNW) in Q4 2021, closing a stake of 62,500 shares — an estimated $79K sold.

Moore Capital Management first reported a position in STLNW in Q2 2020 and held it in 6 quarters. The position peaked at $122K in Q4 2020. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

Moore Capital Management reported no remaining Starling Oncology Warrant position as of Q4 2021 after selling out during the quarter.
Moore Capital Management sold 62,500 Starling Oncology Warrant shares in Q4 2021, an estimated $79K.
Moore Capital Management first reported a position in Starling Oncology Warrant in Q2 2020 and held it in 6 quarters.
Moore Capital Management's Starling Oncology Warrant position peaked at $122K in Q4 2020.
20 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q4 2021.

Based on Moore Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.